Stock AnalizPrivia Health Group, Inc. PRVA
Medical/Nursing Services · IPO 2021 · data as of November 13, 2026
Privia Health Group, Inc. (PRVA) is a healthcare company listed in the US with a market value of about $3.1B. In the twelve months to September 30, 2026 it had revenue of $2.4B and net income of $35M, a net margin of 1.4%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 94.4, a price to free cash flow of 29.0, 5-year revenue growth of 21% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 58% below the current price.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4B | $2.1B | $1.7B | $1.7B | $1.4B | $966M | $817M | $786M |
| Net income | $35M | $23M | $14M | $23M | -$9M | -$188M | $31M | $8M |
| Free cash flow | $108M | — | — | $81M | $47M | $55M | $39M | $19M |
| EPS (diluted) | $0.26 | $0.18 | $0.11 | $0.19 | $-0.08 | $-1.83 | $0.33 | $0.09 |
| Net margin | 1.4% | 1.1% | 0.8% | 1.4% | -0.6% | -19.5% | 3.8% | 1.1% |
| ROIC | — | 3.1% | 1.6% | 2.6% | -2.4% | -40.0% | 11.1% | 13.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 17 analysts is $31.35, 28% above the current price; targets range from $24.00 to $38.00; the consensus rating is “Strong buy”; expected EPS is $0.85 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Privia Health Group’s P/E ratio?
About 94.4, based on the last twelve months of diluted earnings per share (forward P/E about 24.5).
Is Privia Health Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 58% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Privia Health Group pay a dividend?
Not currently.
Is Privia Health Group a good stock to buy?
We do not give buy or sell advice. Privia Health Group scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.